• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Baseline cardiovascular comorbidities, and the influence on cancer treatment decision-making in women with breast cancer
CONCLUSION: While recent guidelines recommend routine assessment of cardiovascular comorbidities in cancer patients prior to initiation of anticancer therapies, this study highlights the prevailing gap in knowledge on how such data may be used to optimise cancer treatment decision-making.PMID:34824616 | PMC:PMC8580595 | DOI:10.3332/ecancer.2021.1293
Source: Ecancermedicalscience - November 26, 2021 Category: Cancer & Oncology Authors: Shridevi Subramaniam Yek-Ching Kong Hafizah Zaharah Cuno S P M Uiterwaal Andrea Richard Nur Aishah Taib Azura Deniel Kok-Han Chee Ros Suzanna Bustamam Mee-Hoong See Alan Fong Cheng-Har Yip Nirmala Bhoo-Pathy Source Type: research

Pages: 1  2  3